Oxford, United Kingdom – 20 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to announce that it has…
Read More
Work to discover drugs for rare and immunological diseases recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2022 – Its work in discovering medicines for rare and…
OxSonics strengthens management team with appointment of Dr Marianna Lalla as Chief Medical Officer Underpins Company’s strategy to expand its pipeline of clinical combination studies Oxford, UK – 6th June…
Financing co-led by new investor Lansdowne Partners and existing investors Oxford Science Enterprises and Parkwalk Advisors, with BGF Investments, Bits x Bites Growth Fund, IP Group, and University of Oxford participating Investment…
Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building New occupiers include CyanoCapture and Ochre Bio Oxford, UK, May 16 2022 – The innovation…
OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that it has partnered with Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases. Under the…
Ochre Bio Launches ‘Liver ICU’ in US to Evaluate Effects of RNA Therapies on Human Liver Performance
Ochre plans to maintain hundreds of discarded donor livers outside the body, mimicking human physiological conditions, to test the efficacy of new RNA therapeutics. Research is expected to advance the…
OrthoSon completes £8.9m expanded Series A to accelerate back pain treatment’s progress to clinic Big Pi Ventures & Yonghua Capital are new international investors in expanded round Oxford, UK, May…
OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi Ventures, with…
OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical…
Oxford Nanopore technology will be used by Genomics England to investigate and validate at increasing scale the benefits of sequencing for improving patient care and advancing research to develop new…
Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon Chairing the Clinical Advisory Group to guide clinical development strategy Oxford, UK, March 21 2022 –…
“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA Could Be Only Authorized SALIVA Rapid Test; Preferred to Nasal swabs by 4x in user testing OTC Self-Test Detects Virus…
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery Program open at no-cost to any academic researcher interested…
MIROBIO CONTINUES EXPANSION OF EXECUTIVE LEADERSHIP TEAM WITH KEY APPOINTMENTS TO ADVANCE DEVELOPMENT OF CHECKPOINT AGONIST ANTIBODIES FOR AUTOIMMUNE DISEASE Sanjay Keswani, MBBS, FRCP to join company as Chief Medical…